Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 15;11:566732. doi: 10.3389/fimmu.2020.566732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 van Dam, Oskam, Kamerling, Arends, Bredewold, Berkowska, van Dongen, Rabelink, van Kooten and Teng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Residual memory and plasma cells after RTX. Absolute counts of (A) total CD19⁺ B-cells (B), Pre-GC B-cells (C), memory B-cells, and (D) plasma cells are shown for each individual patient that received remission-induction therapy with RTX (n = 6). The median is indicated by the thick black line. Red dashed line indicates the mean detection limit for HSFC. Gray area indicates 1–20 analyzed events (E). Median ± IQR fold change as compared to baseline for each B-cell subset per timepoint is shown (F). Mean distribution of B-cell subsets per timepoint during RTX treatment is shown.